General Information of Drug (ID: DMVX19Q)

Drug Name
LYCOGARUBIN B Drug Info
Synonyms LYCOGARUBIN B; CHEMBL439675
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11441783
TTD Drug ID
DMVX19Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
VATALANIB DMY0UEQ Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [4]
Sirna-027 DMZTQD8 Exudative age-related macular degeneration 9B78.3Z Phase 1/2 [5]
PMID22765894C8h DMH5RFU Discovery agent N.A. Investigative [6]
2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 Discovery agent N.A. Investigative [7]
AAL-993 DM35RFH Discovery agent N.A. Investigative [3]
PMID17935989C25 DML8ZBR Discovery agent N.A. Investigative [8]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMX6QMT Discovery agent N.A. Investigative [9]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide DMI3OR9 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
VEGFR1 messenger RNA (VEGFR1 mRNA) TT1VAUK VGFR1_HUMAN Inhibitor [1]

References

1 New cytotoxic bisindole alkaloids with protein tyrosine kinase inhibitory activity from a myxomycete Lycogala epidendrum. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2776-80.
2 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
3 Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
4 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
5 2011 Pipeline of Sirna Therapeutics.
6 The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
7 Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9.
8 Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601.
9 Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
10 Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.